Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0178874 (
tumor progression
)
40,807
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Warburg effect has been recognized as a hallmark of cancer cells for many years, but its modulation mechanism remains a great focus. Our current study found a member of solute carrier family 25 (
SLC25A29
), the main arginine transporter on mitochondria, significantly elevated in various cancer cells. Knockout of
SLC25A29
by CRISPR/Cas9 inhibited proliferation and migration of cancer cells both in vitro and in vivo.
SLC25A29
-knockout cells also showed an altered metabolic status with enhanced mitochondrial respiration and reduced glycolysis. All of above impacts could be reversed after rescuing
SLC25A29
expression in
SLC25A29
-knockout cells. Arginine is transported into mitochondria partly for nitric oxide (NO) synthesis. Deletion of
SLC25A29
resulted in severe decrease of NO production, indicating that the mitochondria is a significant source of NO.
SLC25A29
-knockout cells dramatically altered the variation of metabolic processes, whereas addition of arginine failed to reverse the effect, highlighting the necessity of transporting arginine into mitochondria by
SLC25A29
. In conclusion, aberrant elevated
SLC25A29
in cancer functioned to transport more arginine into mitochondria, improved mitochondria-derived NO levels, thus modulated metabolic status to facilitate increased
cancer progression
.
...
PMID:Elevated mitochondrial SLC25A29 in cancer modulates metabolic status by increasing mitochondria-derived nitric oxide. 2945 13